Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Income from Continuing Operations (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed Income from Continuing Operations for 12 consecutive years, with 7138000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 60.87% to 7138000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 31080000.0 through Dec 2025, down 36.89% year-over-year, with the annual reading at 31080000.0 for FY2025, 36.89% down from the prior year.
  • Income from Continuing Operations hit 7138000.0 in Q4 2025 for vTv Therapeutics, up from 10345000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 841000.0 in Q2 2021 to a low of 10345000.0 in Q3 2025.
  • Historically, Income from Continuing Operations has averaged 6127750.0 across 5 years, with a median of 6054500.0 in 2022.
  • Biggest YoY gain for Income from Continuing Operations was 83.15% in 2021; the steepest drop was 690.11% in 2021.
  • Year by year, Income from Continuing Operations stood at 9483000.0 in 2021, then skyrocketed by 35.78% to 6090000.0 in 2022, then grew by 27.08% to 4441000.0 in 2023, then increased by 0.09% to 4437000.0 in 2024, then crashed by 60.87% to 7138000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for VTVT at 7138000.0 in Q4 2025, 10345000.0 in Q3 2025, and 7380000.0 in Q2 2025.